Vice President of Research and Development
at bit.bio
Sejla Salic-Hainzl received her training as a stem cell biologist in Sasha Mendjan's lab at IMBA. Following a short stay at Signalomics, she joined a team of drug hunters at Haplogen and developed an antiviral drug candidate. At Myllia, she led a team of scientists to develop a programmable endonuclease and utilised functional genomics. In 2020, she joined bit.bio as Director R&D and, later on, Vice President of R&D, where she leads a team of 20+ scientists involved in CRISPR screening, cell line engineering and product development. Sejla is driven by curiosity and enjoys tackling tough scientific challenges.
Got a Question for Sejla Salic-Hainzl?
Get in touch using the contact form linked here and we’ll get back to you shortly.